HCA Healthcare Executive Compensation (FY25)
HCA · Executive and director compensation, fiscal 2022 to 2025
The HCA Healthcare brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): April 28, 2026
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
264 figures on this page: 255 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Samuel Hazen: $23,799,137 → $26,456,606 (11.2% higher)
Say-on-pay support: 93.6% → 93.5% (0.1 points lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is HCA Healthcare's chief executive and what were they paid?
Samuel Hazen was paid $26,456,606 in total compensation as Chief Executive Officer for fiscal 2025. Compared with the $23,799,137 reported for fiscal 2024, Hazen's total was 11.2% higher.
What was HCA Healthcare's say-on-pay result?
Shareholders supported the say-on-pay proposal with 93.5% of votes cast for or against in favor at the meeting held April 23, 2026 for fiscal 2025.
Which companies are in HCA Healthcare's peer group?
The disclosed peer group includes Abbott Laboratories, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company and Cardinal Health, Inc., among others.
What is HCA Healthcare's chief executive pay ratio?
The company reported a chief executive pay ratio of 420:1 for fiscal 2025, against median employee compensation of $62,955.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Samuel Hazen Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
William Rutherford Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Samuel Hazen Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
William Rutherford Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Samuel Hazen Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Michael Marks Executive Vice President and Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
William Rutherford Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Samuel Hazen Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Jon Foster Executive Vice President and Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Michael Marks Executive Vice President and Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | ◇ | ◇ | ◇ |
Michael McAlevey Executive Vice President - Chief Legal and Administrative Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Cuffe Executive Vice President and Chief Clinical Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Jon M. Foster | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jon M. Foster | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael A. Marks | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael A. Marks | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael R. McAlevey | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael R. McAlevey | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael S. Cuffe | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael S. Cuffe | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Samuel N. Hazen | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Samuel N. Hazen | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Samuel Hazen | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| Michael Marks | PSU | ◇ | ◇ | — | — |
| SAR | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — | |
| Michael McAlevey | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| Jon Foster | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| Michael Cuffe | SAR | ◇ | — | ◇ | — |
| SAR | ◇ | — | ◇ | — | |
| SAR | ◇ | — | ◇ | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| SAR | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Thomas F. Frist III Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Michael W. Michelson | ◇ | ◇ | — | — | — | — | ◇ |
Hugh F. Johnston | ◇ | ◇ | — | — | — | — | ◇ |
Wayne J. Riley, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Andrea B. Smith | ◇ | ◇ | — | — | — | — | ◇ |
Nancy-Ann DeParle | ◇ | ◇ | — | — | — | — | ◇ |
Robert J. Dennis | ◇ | ◇ | — | — | — | — | ◇ |
William R. Frist | ◇ | ◇ | — | — | — | — | ◇ |
John W. Chidsey, III | ◇ | ◇ | — | — | — | — | ◇ |
Meg G. Crofton | ◇ | — | — | — | — | — | ◇ |
Samuel N. Hazen served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Abbott Laboratories ABT
- AbbVie Inc. ABBV
- Amgen Inc. AMGN
- Bristol-Myers Squibb Company BMY
- Cardinal Health, Inc. CAH
- Cencora, Inc. COR
- Centene Corp. CNC
- CVS Health Corporation CVS
- Danaher Corporation DHR
- Elevance Health, Inc. ELV
- Eli Lilly and Company LLY
- Gilead Sciences, Inc. GILD
- Humana Inc. HUM
- Johnson & Johnson JNJ
- McKesson Corporation MCK
- Medtronic Inc. MDT
- Merck & Co., Inc. MRK
- Molina Healthcare, Inc. MOH
- Pfizer Inc. PFE
- Stryker Corporation SYK
- Tenet Healthcare Corporation THC
- The Cigna Group CI
- Thermo Fisher Scientific Inc. TMO
- UnitedHealth Group Incorporated UNH
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | April 23, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | April 24, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | April 25, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | April 19, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | April 21, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | April 28, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 1, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | April 26, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | April 26, 2018 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact HCA Healthcare disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where HCA Healthcare sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
264 figures on this page: 255 cited to the filing that reported them, 9 calculated from figures it prints.
255 cited to the filing
9 calculated from the filing
Documents cited
- 0001193125-26-187155
- 0001193125-26-1061422025 Grants of Plan-Based Awards · 2025 Summary Compensation Table · CEO Pay Ratio · Director Compensation. · and 2 more sections
- 0001193125-25-103953
- 0001193125-25-054832Summary Compensation Table
- 0001193125-24-125204
- 0001193125-24-069180
- 0001193125-23-110578
- 0001193125-23-067645Summary Compensation Table
- 0001193125-22-120439
- 0001193125-21-150111
- 0001193125-20-135015
- 0001193125-19-135052
- 0001193125-18-148854Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “HCA Healthcare executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/HCA (accessed 2026).
Short form: data: Velarion
The HCA Healthcare brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about HCA Healthcare and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers HCA Healthcare discloses
The companies named in HCA's own disclosed peer group.
Abbott LaboratoriesAbbVie Inc.Amgen Inc.Bristol-Myers Squibb CompanyCardinal Health, Inc.Cencora, Inc.Centene Corp.CVS Health CorporationDanaher CorporationElevance Health, Inc.Eli Lilly and CompanyGilead Sciences, Inc.Humana Inc.Johnson & JohnsonMcKesson CorporationMedtronic Inc.Merck & Co., Inc.Molina Healthcare, Inc.Pfizer Inc.Stryker CorporationTenet Healthcare CorporationThe Cigna GroupThermo Fisher Scientific Inc.UnitedHealth Group Incorporated
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}